Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00301509|
Recruitment Status : Completed
First Posted : March 13, 2006
Last Update Posted : March 13, 2006
- the impact of combined antiviral therapy (Peginterferon plus ribavirin) on natural history of patients affected with HCV decompensated cirrhosis, after sustained virological response. A controlled study.
- safety and efficacy of antiviral therapy in this population by using a statistically significally number of patients as controls.
|Condition or disease||Intervention/treatment||Phase|
|Liver Cirrhosis, Experimental||Drug: peginterferon and ribavirin||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Outcome of Decompensated Hepatitis C Virus-Related Cirrhotic Patients Treated With Peginterferon Alfa-2b and Ribavirin: Results of a Controlled Study|
|Study Start Date :||January 2002|
|Study Completion Date :||December 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00301509
|Department of Hepatogastroenterology, CSS|
|San Giovanni Rotondo, Foggia, Italy, 71013|
|Principal Investigator:||Angelo Andriulli, Chief||CSS|